Information for the public
Cemiplimab (Libtayo) is available on the NHS. It is a possible treatment for recurrent or metastatic cervical cancer that has progressed (got worse) on or after platinum-based chemotherapy in adults if:
- they have not had immunotherapy, and
- treatment is stopped after 32 cycles (each lasting 3 weeks), or earlier if the cancer progresses or there is unacceptable toxicity.
Recurrent means the cancer has come back after treatment and metastatic means that it has spread to other parts of the body. A treatment cycle involves periods of active treatment and rest (when there is no treatment).
If you are not eligible for cemiplimab but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.
Is this treatment right for me?
Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on shared decision making.
Questions to think about
- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?
Information and support
The NHS webpage on cervical cancer may be a good place to find out more.
These organisations can give you advice and support:
- Cancer Research UK, 0808 800 4040
- Macmillan Cancer Support, 0808 808 0000
You can also get support from your local Healthwatch.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
ISBN: 978-1-4731-9598-1
This page was last updated: